{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:33:28Z","timestamp":1791876808889,"version":"4.3.4"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The effects of adipokines have been investigated in multiple sclerosis (MS) in the literature. Results are uncertain, and subgroups like adropin have not been previously studied. We primarily aimed to determine leptin and adropin levels in MS and their potential use as a biomarker.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study was an experimental research. While 44 MS patients diagnosed according to McDonald criteria were included in the patient group, 40 people without MS diagnosis and risk factors took part in the control group. Demographic data, height, weight, body mass index, blood glucose, thyroid-stimulating hormone, alanine transaminase, aspartate transaminase, creatinine, low-density lipoprotein, leptin, adropin levels, presence of hypertension, diabetes mellitus, coronary artery disease were recorded. Expanded disability status scale and disease duration were also evaluated in the patient group. Our data were presented as mean\u200a\u00b1\u200astandard deviations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean blood leptin value of the patient group (6.12\u200a\u00b1\u200a5.34\u200ang\/mL) was significantly lower than the value of the control group (13.02\u200a\u00b1\u200a8.25\u200ang\/mL) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). The patient group had a mean adropin level of 504.12\u200a\u00b1\u200a311.17\u200ang\/mL, which was significantly lower than that of the control group (747.0\u200a\u00b1\u200a309.42\u200ang\/mL) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). Statistically insignificant differences were found between their body mass index, glucose, alanine transaminase, aspartate transaminase, thyroid-stimulating hormone, low-density lipoprotein levels (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&gt;\u200a.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This is the first study that has evaluated adropin levels in patients with MS. The relationship between MS and leptin levels is still unclear. Therefore, our study might be helpful to elucidate MS pathogenesis and provide supportive criteria for diagnosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027247","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T13:21:46Z","timestamp":1631884906000},"page":"e27247","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Investigation of blood leptin and adropin levels in patients with multiple sclerosis"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-1144","authenticated-orcid":false,"given":"Ufuk","family":"Cinkir","sequence":"first","affiliation":[{"name":"Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent Sinan","family":"Bir","sequence":"additional","affiliation":[{"name":"Pamukkale University Faculty of Medicine, Denizli, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senay","family":"Topsakal","sequence":"additional","affiliation":[{"name":"Pamukkale University Faculty of Medicine, Denizli, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esin","family":"Avci Cicek","sequence":"additional","affiliation":[{"name":"Pamukkale University Faculty of Medicine, Denizli, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Tekin","sequence":"additional","affiliation":[{"name":"Pamukkale University Faculty of Medicine, Denizli, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology","volume":"9","author":"Koch-Henriksen","year":"2010","journal-title":"Lancet Neurol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"A387","DOI":"10.1016\/j.autrev.2009.11.010","article-title":"Multiple sclerosis: geoepidemiology, genetics and the environment","volume":"9","author":"Milo","year":"2010","journal-title":"Autoimmun Rev"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.4049\/jimmunol.1200935","article-title":"Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses","volume":"189","author":"Procaccini","year":"2012","journal-title":"J Immunol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/postgradmedj-2017-135397","article-title":"Association between circulating leptin levels and multiple sclerosis: a systematic review and meta-analysis","volume":"94","author":"Xie","year":"2018","journal-title":"Postgrad Med J"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2018.07.011","article-title":"Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis","volume":"323","author":"Kvistad","year":"2018","journal-title":"J Neuroimmunol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cmet.2008.10.011","article-title":"Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism","volume":"8","author":"Kumar","year":"2008","journal-title":"Cell Metab"},{"issue":"(11 suppl)","key":"R10-20250504","first-page":"S185","article-title":"Adropin is a novel regulator of endothelial function","volume":"122","author":"Lovren","year":"2010","journal-title":"Circulation"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.2337\/db14-0388","article-title":"Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin","volume":"63","author":"Gao","year":"2014","journal-title":"Diabetes"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jpeds.2013.05.040","article-title":"Circulating adropin concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function","volume":"163","author":"Gozal","year":"2013","journal-title":"J Pediatr"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"25858","DOI":"10.1074\/jbc.M313505200","article-title":"NB-3\/Notch1 pathway via Deltex1 promotes neural progenitor cell differentiation into oligodendrocytes","volume":"279","author":"Cui","year":"2004","journal-title":"J Biol Chem"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000093895","article-title":"Prevalence of multiple sclerosis door-to-door survey in Maltepe, Istanbul, Turkey","volume":"27","author":"Turk Boru","year":"2006","journal-title":"Neuroepidemiology"},{"key":"R15-20250504","first-page":"193","article-title":"Prevalence of multiple sclerosis in the metropolitan area of Edirne City, Turkey","volume":"28","author":"\u00c7elik","year":"2011","journal-title":"Balkan Med J"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5505\/kjms.2017.61587","article-title":"The evaluation of clinical, demographic, radiological characteristics and treatment response of multiple sclerosis patients in Thrace region","volume":"7","author":"\u00c7elebi","year":"2017","journal-title":"Kafkas J Med Sci"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/1352458512437814","article-title":"Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia","volume":"18","author":"Marrie","year":"2012","journal-title":"Mult Scler"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.yfrne.2010.06.002","article-title":"Leptin in human physiology and therapeutics","volume":"31","author":"Dardeno","year":"2010","journal-title":"Front Neuroendocrinol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cmet.2013.05.010","article-title":"Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives","volume":"18","author":"Dalamaga","year":"2013","journal-title":"Cell Metab"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.physbeh.2004.02.014","article-title":"Leptin signaling","volume":"81","author":"Ahima","year":"2004","journal-title":"Physiol Behav"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/0003-4819-152-2-201001190-00008","article-title":"Narrative review: the role of leptin in human physiology: emerging clinical applications","volume":"152","author":"Kelesidis","year":"2010","journal-title":"Ann Intern Med"},{"key":"R22-20250504","first-page":"01","article-title":"Serum leptin levels in treatment-naive patients with clinically isolated syndrome or relapsing- remitting multiple sclerosis","author":"Evangelopoulos","year":"2014","journal-title":"Autoimmune Dis"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0165-5728(03)00154-1","article-title":"Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta","volume":"139","author":"Batocchi","year":"2003","journal-title":"J Neuroimmunol"},{"key":"R24-20250504","first-page":"3087","article-title":"mTOR, S6 and AKT expression in relation to proliferation and apoptosis\/autophagy in glioma","volume":"29","author":"Annovazzi","year":"2009","journal-title":"Anticancer Res"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1515\/revneuro-2012-0001","article-title":"Role of mammalian target of rapamycin in hypoxic or ischemic brain injury: potential neuroprotection and limitations","volume":"23","author":"Chen","year":"2012","journal-title":"Rev Neurosci"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"25976","DOI":"10.1074\/jbc.M114.576058","article-title":"Adropin is a brain membrane-bound protein regulating physical activity via the NB-3\/Notch signaling pathway in mice","volume":"289","author":"Wong","year":"2014","journal-title":"J Biol Chem"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.molmet.2015.01.005","article-title":"Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance","volume":"4","author":"Gao","year":"2015","journal-title":"Mol Metab"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/dneu.20742","article-title":"Contribution of the neural cell recognition molecule NB-3 to synapse formation between parallel fibers and Purkinje cells in mouse","volume":"69","author":"Sakurai","year":"2009","journal-title":"Dev Neurobiol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.peptides.2016.03.009","article-title":"Adropin reduces paracellular permeability of rat brain endothelial cells exposed to ischemia-like conditions","volume":"81","author":"Yang","year":"2016","journal-title":"Peptides"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4103\/1673-5374.131581","article-title":"Regulation of extracellular signal-regulated kinase 1\/2 influences hippocampal neuronal survival in a rat model of diabetic cerebral ischemia","volume":"9","author":"Zhao","year":"2014","journal-title":"Neural Regen Res"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.nbd.2003.08.020","article-title":"Regulation of hypoxia-inducible factor 1alpha and induction of vascular endothelial growth factor in a rat neonatal stroke model","volume":"14","author":"Mu","year":"2003","journal-title":"Neurobiol Dis"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1460-9568.2005.03985.x","article-title":"Akt is altered in an animal model of Huntington's disease and in patients","volume":"21","author":"Colin","year":"2005","journal-title":"Eur J Neurosci"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1471-4159.2004.02949.x","article-title":"Activation of Akt\/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology","volume":"93","author":"Griffin","year":"2005","journal-title":"J Neurochem"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/cdd.2009.127","article-title":"P.H. domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K\/Akt pro-survival pathway in Huntington's disease striatum","volume":"17","author":"Saavedra","year":"2010","journal-title":"Cell Death Differ"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pharmthera.2007.02.002","article-title":"Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease","volume":"114","author":"Burke","year":"2007","journal-title":"Pharmacol Ther"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/carcin\/bgm052","article-title":"PTEN, more than the AKT pathway","volume":"28","author":"Blanco-Aparicio","year":"2007","journal-title":"Carcinogenesis"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.3389\/fnana.2015.00048","article-title":"Neuroprotective effects of DAHP and Triptolide in focal cerebral ischemia via apoptosis inhibition and PI3K\/Akt\/mTOR pathway activation","volume":"9","author":"Li","year":"2015","journal-title":"Front Neuroanat"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1126\/science.1124147","article-title":"Hypothalamic mTOR signaling regulates food intake","volume":"312","author":"Cota","year":"2006","journal-title":"Science"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:32:08Z","timestamp":1746340328000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027247"}},"subtitle":["A CONSORT-clinical study"],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":38,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027247","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"2021-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}